<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110291</url>
  </required_header>
  <id_info>
    <org_study_id>XRP 6976A/6022</org_study_id>
    <nct_id>NCT01110291</nct_id>
  </id_info>
  <brief_title>Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events</brief_title>
  <acronym>Docetaxel</acronym>
  <official_title>Activity of CYP3A and Genotypes of CYP3A5 and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vaasa Central Hospital, Vaasa, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>medbase Oy Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Twenty patients with verified high risk breast cancer will be included in the study. Patients&#xD;
      will receive three cycles of docetaxel followed by three cycles of CEF for their adjuvant&#xD;
      treatment. The phenotype of CYP3A and the genotype of CYP3A5 and MDR1 will be assessed. Also&#xD;
      the effect of docetaxel in the activity of CYP3A will be measured by peroral midazolam.&#xD;
&#xD;
      Primary Object:&#xD;
&#xD;
      The primary object of this study is to define, if it is possible to predict the clearance&#xD;
      and/ or toxicity of docetaxel by assessing&#xD;
&#xD;
        -  activity of CYP3A4 by midazolam test (CYP3A4 phenotype)&#xD;
&#xD;
        -  CYP3A5 genotype&#xD;
&#xD;
        -  MDR1 genotype&#xD;
&#xD;
      Secondary object:&#xD;
&#xD;
      The secondary object of this study is to define whether the treatment with docetaxel alters&#xD;
      the activity of CYP3A4 enzyme in previously untreated breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>docetaxel toxicity</measure>
    <description>There were no specific outcome measures in this study. The chemotherapy was given in a predetermined schedule and additionally blood samples were drawn for genotyping. The adverse events were recorded and compared with the data from genotyping.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <description>No specific outcome measures. Survival data was collected and compared with the data from genotyping.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>CYP3A Phenotyping</condition>
  <condition>CYP3A5 and MDR1 Genotyping</condition>
  <condition>Docetaxel Toxicity</condition>
  <condition>Associations Between Genetic Data and Docetaxel Toxicity</condition>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>Twenty patients with verified high risk breast cancer will be included in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel + CEF</intervention_name>
    <description>Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.&#xD;
Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times.</description>
    <arm_group_label>Breast cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for genotyping and phenotyping as well as analysis of docetaxel concentrations.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty patients with verified high risk breast cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects may be included in the study only if they meet all of the following criteria:&#xD;
&#xD;
          1. The patient has received information on the purpose of the study and the meaning of&#xD;
             the treatment, and has given verbal and written consent to participate in the study.&#xD;
             The patient is accessible for treatment and follow-up.&#xD;
&#xD;
          2. Histologically verified diagnosis of breast cancer&#xD;
&#xD;
          3. High risk for recurrence ( node positive or node negative if T2 with histological&#xD;
             grade 2 or 3, or Pgr negative)&#xD;
&#xD;
          4. No metastases&#xD;
&#xD;
          5. Females, age =&lt;60&#xD;
&#xD;
          6. No concomitant regular medication which is either substrate, inducer or inhibitor of&#xD;
             CYP3A4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study for any of the following reasons:&#xD;
&#xD;
          1. Poor performance status,&gt;=2 according to WHO&#xD;
&#xD;
          2. Inadequate bone marrow reserve defined as:&#xD;
&#xD;
               -  hemoglobin &lt; 100 g/L&#xD;
&#xD;
               -  leukocytes &lt; 3.0 x 10E9/L or neutrophiles &lt; 1.5 x 10E9/L&#xD;
&#xD;
               -  plateless &lt; 120 x 10E9/L&#xD;
&#xD;
          3. Inadequate liver function defined as:&#xD;
&#xD;
               -  ALAT is &gt; 1.5 x units of normal level&#xD;
&#xD;
               -  elevated bilirubin (unless verified Gilbert´s syndrome)&#xD;
&#xD;
               -  alkaline phosphatase is &gt; 2.5 x units of normal level&#xD;
&#xD;
          4. History of concomitant serious physical or psychiatric disease, which makes a regular&#xD;
             cytotoxic treatment impossible&#xD;
&#xD;
          5. cardiac insufficience; severe arrhythmia; severe hypertension; cardiac infarction&#xD;
             within one year or other active cardiac disease&#xD;
&#xD;
          6. pregnant or lactating patients&#xD;
&#xD;
          7. abuse of alcohol or any narcotic substances&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Hilli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liisa Sailas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vaasa Central Hospital, Vaasa, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sirkku Jyrkkiö, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seppo Pyrhönen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kari Laine, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>medbase Oy Ltd, Turku, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <last_update_submitted>April 26, 2010</last_update_submitted>
  <last_update_submitted_qc>April 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Johanna Hilli</name_title>
    <organization>Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland</organization>
  </responsible_party>
  <keyword>docetaxel toxicity</keyword>
  <keyword>CYP3A activity</keyword>
  <keyword>CYP3A5</keyword>
  <keyword>MDR1</keyword>
  <keyword>peroral midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

